Rice and Baylor receive $2.8 million to suppress inflammation and lung damage in ARDS patients

Rice University and Baylor College of Medicine have received $2.8 million in funding from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), for research on reducing inflammation and lung damage in acute respiratory distress syndrome (ARDS) patients.

Biostax and Immgenuity to expedite HIV immunotherapies

IMTVO14 immunotherapy comprises a genetically modified HIV virus. Credit: Corona Borealis Studio/Shutterstock.com. Biostax and Immgenuity have entered a research collaboration agreement to expedite the development

August 30, 2023

Novel vaccine against Lyme disease reported to be safe and effective

Researchers determine the safety and immunogenicity of a novel candidate vaccine against Lyme borreliosis.

July 11, 2023

‘Cell therapy without cells’: Capstan raises $175M to test in vivo CAR-T

Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less

March 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

​​​​​​​Rice and Baylor receive $2.8 million to suppress inflammation and lung damage in ARDS patients